News und Analysen
These 3 Stocks Have Doubled Investors' Money in 2017
The stock market has done well so far in 2017, with gains of almost 10% for the S&P 500 and even greater rises for some other major market benchmarks. A small number of top-performing stocks have done
Will the Drug Pricing Executive Order Help Big Pharma?
The cost of healthcare has climbed at a rate considerably above that of inflation, and high drug costs are a big factor. During his campaign, President Trump indicated that he would take steps to
Will the Drug Pricing Executive Order Help Big Pharma?
The cost of healthcare has climbed at a rate considerably above that of inflation, and high drug costs are a big factor. During his campaign, President Trump indicated that he would take steps to
Will the Drug Pricing Executive Order Help Big Pharma?
The cost of healthcare has climbed at a rate considerably above that of inflation, and high drug costs are a big factor. During his campaign, President Trump indicated that he would take steps to
Pfizer Is Set to Lose Its No. 1 Spot Among Drugmakers: Here's Why It Doesn't Matter
Pfizer (NYSE: PFE) stands at the top of the mountain when it comes to prescription drug sales. Last year, the big pharma company made $45.9 billion from prescription drugs, well ahead of runners-up
Pfizer Is Set to Lose Its No. 1 Spot Among Drugmakers: Here's Why It Doesn't Matter
Pfizer (NYSE: PFE) stands at the top of the mountain when it comes to prescription drug sales. Last year, the big pharma company made $45.9 billion from prescription drugs, well ahead of runners-up
These 3 Charts Don't Lie: Gilead Sciences Needs an Acquisition
Pretty much everyone familiar with Gilead Sciences (NASDAQ: GILD) wants the company to make an acquisition. Many think the big biotech desperately needs one (or more) to reenergize the lethargic
These 3 Charts Don't Lie: Gilead Sciences Needs an Acquisition
Pretty much everyone familiar with Gilead Sciences (NASDAQ: GILD) wants the company to make an acquisition. Many think the big biotech desperately needs one (or more) to reenergize the lethargic
These 3 Charts Don't Lie: Gilead Sciences Needs an Acquisition
Pretty much everyone familiar with Gilead Sciences (NASDAQ: GILD) wants the company to make an acquisition. Many think the big biotech desperately needs one (or more) to reenergize the lethargic
Roundtable: 1 Stock I'm Never Selling
Stocks that are worth buying and holding for exceptionally long periods of time are far less common than most investors may think. Changes in underlying market conditions, after all, can knock even
Roundtable: 1 Stock I'm Never Selling
Stocks that are worth buying and holding for exceptionally long periods of time are far less common than most investors may think. Changes in underlying market conditions, after all, can knock even
What Managed Care Organizations Are, and How Investors Can Profit From Them
Most Americans get their healthcare through a managed care organization, but nearly no one truly knows the ins and outs of the health insurance program they have. Managed care organizations are plans
What Managed Care Organizations Are, and How Investors Can Profit From Them
Most Americans get their healthcare through a managed care organization, but nearly no one truly knows the ins and outs of the health insurance program they have. Managed care organizations are plans
3 Stocks That Turned $1,000 Into at Least $2,017 in 12 Months
Although there is some truth in the saying that it takes money to make money, that doesn't mean investors can't start small and reap big rewards. With little more than $1,000 in your account, you can
Is Aurinia Pharmaceuticals' Management Its Best Asset?
Richard Glickman was the founder and CEO of Aspreva Pharmaceuticals, a small company that he sold for $915 million in 2008 after it developed CellCept, a treatment that today is commonly used in lupus
Down 14.8%: Is Celldex Therapeutics Stock an Incredible Bargain?
Despite a widespread rally across the biotech landscape last month, the struggling clinical-stage cancer company Celldex Therapeutics (NASDAQ: CLDX) still managed to shed 14.8% of its value in
5 Things You Need to Know About Marijuana Stock Zynerba Pharmaceuticals
There are three different general types of marijuana stocks on the market. Some are marijuana growers. Others provide supplies to marijuana growers. Then there's the third type of marijuana stock: the
Is It Time to Sell Portola?
Portola Pharmaceuticals' (NASDAQ: PTLA) stock recently jumped 45% on the news that it won its first FDA approval.In this segment of Industry Focus: Healthcare, Motley Fool analyst Kristine Harjes and
No Surprise! Amicus Therapeutics Hits Up Investors for More Cash
Amicus Therapeutics (NASDAQ: FOLD) will be able to submit its Fabry disease drug Galafold to the FDA for consideration, a reversal of fortune that sent shares skyrocketing earlier this week. While
A New Cancer Treatment Is on the Way -- and Cancer Better Be Scared
A key FDA advisory committee voted unanimously on Wednesday to recommend approval of Novartis (NYSE: NVS) ground-breaking drug for pediatric and young adult B-cell acute lymphoblastic leukemia, or
A New Cancer Treatment Is on the Way -- and Cancer Better Be Scared
A key FDA advisory committee voted unanimously on Wednesday to recommend approval of Novartis (NYSE: NVS) ground-breaking drug for pediatric and young adult B-cell acute lymphoblastic leukemia, or
A New Cancer Treatment Is on the Way -- and Cancer Better Be Scared
A key FDA advisory committee voted unanimously on Wednesday to recommend approval of Novartis (NYSE: NVS) ground-breaking drug for pediatric and young adult B-cell acute lymphoblastic leukemia, or
How Biogen Inc. Makes Most of Its Money
Biogen (NASDAQ: BIIB) recorded $2.38 billion in product revenue in the first quarter -- a nice haul for a large biotech -- but 40% of its sales came from its top-selling multiple-sclerosis drug
How Biogen Inc. Makes Most of Its Money
Biogen (NASDAQ: BIIB) recorded $2.38 billion in product revenue in the first quarter -- a nice haul for a large biotech -- but 40% of its sales came from its top-selling multiple-sclerosis drug
How Biogen Inc. Makes Most of Its Money
Biogen (NASDAQ: BIIB) recorded $2.38 billion in product revenue in the first quarter -- a nice haul for a large biotech -- but 40% of its sales came from its top-selling multiple-sclerosis drug